CompletedNot Applicable

Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit

Egypt70 participantsStarted 2024-07-01

Plain-language summary

The aim of this study is to evaluate the effect of pentoxifylline for control of contrast induced nephropathy in chronic kidney diseased patients in intensive care unit.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age from 18 to 65 years. * Both sexes. * The presence of chronic kidney disease (CKD) is defined according to the National Kidney Foundation-kidney disease Outcomes Quality Initiative guidelines with second or third stage. * Urgent patients expected taking dye in stable cases of cardiac catheterization or pulmonary embolism with Geneva score (4-11). Exclusion Criteria: * Patients with CKD on renal replacement therapy. * Respiratory failure. * Cardiac failure. * Liver failure. * Methylxanthines hypersensitivity.

What they're measuring

Incidence of contrast induced nephropathy

Timeframe: 48 hours after contrast procedure.

Trial details

NCT IDNCT07561801

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Pentoxifylline trials